Key facts
- This page summarizes Thomas Charles Reilly's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Mar 2022, 15:18.
Thomas Charles Reilly - 25 Feb 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TVRD
- Reported as of
- 25 Feb 2022
- Net transaction value
- +$54,877
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2022, 15:18:18 UTC
- Prior SEC filing
- 21 Dec 2021
- Next SEC filing
- 04 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darren DeStefano, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Charles Reilly filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 01 Mar 2022.
Change
- Previous filing in this sequence was filed on 21 Dec 2021.
- Current net transaction value: +$54,877.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +138%
- Price
- $0.000000
- Shares after
- 34,522
- Date
- 25 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
CARA
transaction
Common Stock
Award
- Transaction value
- $54,877
- Shares
- +5,333
- Change %
- +15%
- Price
- $10.29
- Shares after
- 39,855
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARA
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 25 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $10.46
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.
Footnote F2
Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 28, 2022. The vested shares represents the last of three possible vesting events of the total number of shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
Footnote F3
The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.